The Dark Secret in Every Miscarriage Treatment

A staggering number of women are walking out of hospitals and clinics after miscarrying, unaware that the treatment intended to help them is actually causing more harm. Dilation and curettage (D&C), the standard surgical procedure for miscarriage management, carries a 17% risk of intrauterine adhesions – scar tissue inside the uterus – according to a landmark meta-analysis published in 2025. This complication can lead to infertility, preterm delivery, and even peripartum hemorrhage.

The D&C procedure is inherently blind, relying on feel rather than visualization. Surgeons insert an instrument past the cervix, removing tissue without benefit of a camera or real-time ultrasound guidance. This approach may seem outdated, but it’s been passed down through generations of physicians with little innovation.

In contrast, hysteroscopic morcellation offers a safer alternative. By inserting a miniature camera and removing tissue under full visualization, surgeons can significantly reduce the risk of adhesions. Dr. Kirsten Sasaki’s study in the Journal of Minimally Invasive Gynecology found an astonishing 0.6% adhesion rate with this technique.

However, hysteroscopic morcellation is not widely offered to women due to economic and systemic factors that have entrenched D&C as the default procedure. The training pipeline has barely changed in decades, leaving new physicians to learn and perpetuate this outdated approach. As a result, women suffer unnecessary complications, and employers bear significant costs downstream.

Fertility benefits often don’t account for the hidden expenses associated with D&C’s long-term complications – adhesions, corrective surgeries, and even placenta accreta spectrum. Black and Hispanic/Latinx patients are disproportionately affected, as they’re more likely to receive post-miscarriage surgical care in emergency settings. In contrast, White and higher-income women tend to receive scheduled D&Cs in controlled outpatient settings where a surgeon familiar with hysteroscopic morcellation is more likely to practice.

The disparity in treatment options raises fundamental questions about access to healthcare. If hysteroscopic morcellation offers a safer and more effective solution, why isn’t it being made available to all women? The answer lies not only in the training gap but also in the inertia of established practices – a perfect storm that prioritizes cost savings over patient well-being.

To address this issue, the medical community must confront the fact that hysteroscopic morcellation is often overlooked. Surgeons need to be trained in this procedure, and hospitals must update their protocols to prioritize visualization-based procedures. Policymakers should recognize the long-term benefits of investing in safer, more effective treatments – not just for women’s health but also for employers’ bottom lines.

Ultimately, the miscarriage treatment landscape is a microcosm of systemic problems within healthcare. It reveals the tension between cost containment and patient outcomes, highlighting the need for more nuanced discussions about value-based care. As we work to improve this complex system, it’s clear that it’s time to rethink the way we treat women who miscarry – before they become just another statistic in the medical establishment’s inertia.